Physician profile
Scott Wiener
NPI 1922333996
$1,432,524.11
in general payments reported to CMS, 2019-2025
27 companies · $526K in 2025
The $526K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $39K · 2021: $61K · 2022: $135K · 2023: $293K · 2024: $283K · 2025: $526K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $464K · Travel and Lodging: $242K · Consulting Fee: $224K · Honoraria: $130K · Food and Beverage: $42K · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $464,033.65 |
| Travel and Lodging | $241,944.83 |
| Consulting Fee | $223,800.00 |
| Honoraria | $130,105.50 |
| Food and Beverage | $41,891.83 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $455,060.01 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $347,976.38 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $291,071.51 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Alkermes, INC. | $143,482.09 | 2019-2024 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $91,872.09 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $63,845.68 | 2020-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $30,493.54 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $1,725.26 | 2021-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $1,582.11 | 2020-2022 | |
| Neuronetics, INC. | $1,168.90 | 2024 | Neurostar Tms Therapy System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $940.10 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $814.69 | 2020-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $478.52 | 2019-2022 | |
| Abbvie INC. | $405.02 | 2021-2024 | |
| Lundbeck LLC | $324.52 | 2019-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $282.55 | 2020-2022 | |
| Bausch Health US, LLC | $251.42 | 2021-2022 | |
| Stryker Corporation | $175.00 | 2019 | |
| Allergan, INC. | $173.63 | 2020-2021 | |
| Sage Therapeutics, LLC | $115.34 | 2025 | Zurzuvae |
| Corium, LLC | $78.99 | 2022-2025 | Azstarys |
| Tris Pharma INC | $66.85 | 2023-2024 | Dyanavel Xr |
| Tempus Ai, INC | $61.06 | 2024 | |
| Janssen Scientific Affairs, LLC | $29.37 | 2022 | |
| Adlon Therapeutics L.P. | $24.20 | 2020 | |
| Eisai INC. | $12.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wiener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.